Mr. Gerald Solensky Jr. reports

ZOMEDICA APPOINTS TWO ANIMAL HEALTH VETERANS TO BOARD OF DIRECTORS

Zomedica Pharmaceuticals Corp. has appointed Jane Eagleson and Tom Robitaille to its board of directors, effective immediately. These appointments expand the board to eight directors, five of whom are independent.

"Together, Jane and Tom bring a combined 60 years of global animal health experience to our board of directors," stated chairman and chief executive officer Gerald Solensky Jr. "The addition of these two independent directors ensures Zomedica will continue to benefit from diverse but complementary perspectives, skills and insights as we continue to build the business."

Ms. Eagleson

A veterinarian with more than 30 years of experience in animal health pharmaceutical development, Ms. Eagleson is currently vice-president of clinical and regulatory affairs at Nexvet Biopharma, a veterinary biotherapeutics company. She concurrently serves, since January, 2013, as owner of Bleecker Street Consulting, an animal health consulting firm that specializes in pharmaceutical development strategy in North America, Europe and the Oceania markets.

From September, 2007, through December, 2012, Ms. Eagleson held various leadership positions with Argenta, a pharmaceutical contract research and contract manufacturing organization. She joined Argenta as head of clinical research and development and elevated to head of growth strategies where she assumed overall ownership of the company's strategic plan.

Prior to that, Ms. Eagleson served in several senior director roles with Pfizer Inc. from December, 1999, through February, 2007, leaving the company as senior director of Asian business development, where she was based in India and responsible for strategic planning and execution of Asian business initiatives for both animal health and human health organizations.

Before Pfizer, Ms. Eagleson was a director with Merial from 1991 to 1997 and served as research veterinarian with Merck Animal Health from 1985 to 1991. She has a master of veterinary science in immunology from Massey University and bachelor of veterinary science (U.S. doctor of veterinary medicine equivalent) from the University of Sydney. She has also authored more than 35 publications in peer-reviewed journals.

Mr. Robitaille

A result-focused international business leader with 30 years of animal health experience, Mr. Robitaille is currently vice-president of veterinary channel development at Blue Buffalo Company, a premium, all-natural pet food company.

Prior to that, Mr. Robitaille held various director level and senior management positions during his 19-year career with the animal health pharmaceutical company Vetoquinol SA Inc. Mr. Robitaille was the Americas group director from September, 2006, through October, 2015, where he managed affiliates and regional distributors in Canada, the United States, Mexico and Brazil. From October, 2004, to October, 2006, he was responsible for veterinary pharmaceutical operations in the United Kingdom, Ireland, Belgium and the Netherlands as managing director. He also served as director of international development from October, 2001, through September, 2004, where he contributed to an increase in sales and profit in Eastern Europe, Asia-Pacific, Africa and Latin America.

Before Vetoquinol, Mr. Robitaille was a product manager with Elanco, the animal health division of Eli Lilly and Company, and prior thereto started his animal health career serving in various sales and marketing positions throughout Canada, the U.S., Europe and the Middle East with Sandoz, a generic pharmaceuticals company. Mr. Robitaille has a master of business administration from the University of Warwick and bachelor of science degree from Concordia University.

We seek Safe Harbor.